Premium
Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma
Author(s) -
Parakh Sagun,
Nguyen Rebecca,
Opie Jacinta M,
Andrews Miles C
Publication year - 2017
Publication title -
australasian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.67
H-Index - 53
eISSN - 1440-0960
pISSN - 0004-8380
DOI - 10.1111/ajd.12488
Subject(s) - medicine , pembrolizumab , immunosuppression , dermatology , bullous pemphigoid , melanoma , metastatic melanoma , ipilimumab , toxicity , immunotherapy , pemphigoid , adverse effect , immunology , cancer , cancer research , antibody
Dermatological toxicity is one of the most commonly reported immune‐related adverse events in patients receiving checkpoint inhibitor immunotherapy. We report the gradual development of a widespread bullous pemphigoid‐like reaction in a metastatic melanoma patient 8 months after commencing treatment with the programmed‐death‐1 ( PD ‐1) inhibitor pembrolizumab, requiring prolonged corticosteroid therapy. This case highlights the potential for insidious and late development of severe cutaneous toxicity following PD ‐1 inhibitor therapy and suggests that even prolonged immunosuppression may not necessarily compromise the efficacy of PD ‐1 inhibition in advanced melanoma.